CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Mucinex +1 moredrug
Likely dose
Mucinex 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01114581
NCT01114581Phase 2Completed
CompareCT.gov

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Reckitt Benckiser LLC·interventional·Posted May 3, 2010·Updated Sep 19, 2018

In Brief

A Phase 2 clinical trial evaluating Mucinex and Placebo for Acute Respiratory Infection. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 3, 2010
Enrollment StartApr 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.2 years ago

Interventions

Mucinexdrug

Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study

Placebodrug

Placebo given as 2 tablets